Research involving mice and samples from patients with multiple sclerosis reveals how anti-CD20 antibodies such as ocrelizumab protect neurons in gray matter, and ties the treatment’s effects to elevated levels of BAFF.
B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans
Posted in biotech/medical, neuroscience